Tocilizumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.

Marya GhazipuraMadalina MacreaDerrick HermanHayley Barnes Shandra Lee KnightRichard M SilverSydney B MontesiGanesh RaghuTanzib Hossain

Published in: Annals of the American Thoracic Society (2023)

Tocilizumab use in patients with SSc-ILD is associated with less disease progression and a better toxicity profile compared to placebo. However, the quality of evidence is very low, and large, prospective studies dedicated to assessing tocilizumab specifically for SSc-ILD are needed.

Keyphrases

interstitial lung disease
rheumatoid arthritis
systemic sclerosis
juvenile idiopathic arthritis
rheumatoid arthritis patients
disease activity
idiopathic pulmonary fibrosis
oxidative stress
randomized controlled trial
case control
double blind